Anthony Floyd, PhD
Anthony is a Research Associate Professor, providing clinical trial and regulatory expertise in the treatment and prevention of substance use disorder, in particular opioid use disorder. He has directed numerous clinical trials and program evaluations in both community treatment and emergency department settings. Dr. Floyd has a secondary focus in firearm injury prevention research, which examines many of the same underlying public health concerns as substance use disorder. In addition, Anthony leads a team from Washington in a multi-site, multi-state study, examining the effectiveness of an opioid safety and education training program aimed at pharmacists in community-based settings.
Department Affiliations
Centers/Programs
Scholarly Expertise
Recent Publications
Adolescent and Young Adult Access to Opioid Use Disorder Care.
(2025 Jun 12)
Pediatrics
Ball A, Winstead T, Singh S, Floyd A, Banta-Green C
(2025 Jun 12)
Pediatrics
Ball A, Winstead T, Singh S, Floyd A, Banta-Green C
Community-Based Medications First for Opioid Use Disorder - Care Utilization and Mortality Outcomes.
(2024)
Subst Abuse Rehabil 15(): 173-183
Banta-Green CJ, Owens MD, Williams JR, Floyd AS, Williams-Gilbert W, Kingston S
(2024)
Subst Abuse Rehabil 15(): 173-183
Banta-Green CJ, Owens MD, Williams JR, Floyd AS, Williams-Gilbert W, Kingston S
Policies, adaptations, and ongoing challenges to naloxone, buprenorphine and nonprescription syringe access across four-states: Findings from an environmental scan and key informant interviews.
(2024 Jun)
Drug Alcohol Depend Rep 11(): 100243
Floyd AS, Silcox J, Strickler G, Nong T, Blough M, Bolivar D, Rabin M, Bratberg J, Irwin AN, Hartung DM, Hansen RN, Bohler R, Green TC
(2024 Jun)
Drug Alcohol Depend Rep 11(): 100243
Floyd AS, Silcox J, Strickler G, Nong T, Blough M, Bolivar D, Rabin M, Bratberg J, Irwin AN, Hartung DM, Hansen RN, Bohler R, Green TC
"I go out of my way to give them an extra smile now:" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials.
(2024 May)
Res Social Adm Pharm 20(5): 512-519
Irwin AN, Gray M, Ventricelli D, Boggis JS, Bratberg J, Floyd AS, Silcox J, Hartung DM, Green TC
(2024 May)
Res Social Adm Pharm 20(5): 512-519
Irwin AN, Gray M, Ventricelli D, Boggis JS, Bratberg J, Floyd AS, Silcox J, Hartung DM, Green TC
The Cost of Safe Injection: Insights on Nonprescription Syringe Price Variability From Systematic Secret Shopping.
(2024 Apr)
Subst Use Addctn J 45(2): 201-210
Blough MJ, Rocha A, Bratberg J, Silcox J, Bolivar D, Floyd AS, Gray M, Green TC
(2024 Apr)
Subst Use Addctn J 45(2): 201-210
Blough MJ, Rocha A, Bratberg J, Silcox J, Bolivar D, Floyd AS, Gray M, Green TC
Show complete publication list »
